https://www.financialmagazin.com/time-to-sector-perform-concordia-healthcare-nasdaqcxrx-cibc-says/
How CIBC Rates Concordia Healthcare (NASDAQ:CXRX)
Stock research analysts at CIBC placed “Sector Perform” rating on Concordia Healthcare (NASDAQ:CXRX). The firm began coverage on CXRXin a report issued to clients on Monday, 30 November.
Out of 5 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $105 is the highest target while $42.50 is the lowest. The $66.90 average target is 73.41% above today’s ($38.58) stock price. Concordia Healthcare Corp. was the topic in 10 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Mackie upgraded the stock on October 19 to “Speculative Buy” rating. Scotia Capital maintained the shares of CXRX in a report on October 16 with “Sector Outperform” rating.
About 23,734 shares traded hands. Concordia Healthcare Corp (NASDAQ:CXRX) has declined 49.89% since April 24, 2015 and is downtrending. It has underperformed by 49.00% the S&P500.
More notable recent Concordia Healthcare Corp (NASDAQ:CXRX) news were published by:Midasletter.com which released: “Concordia Healthcare Corp (CXRX): Bargain or Valeant Pharmaceuticals Intl Inc …” on October 22, 2015, also Fool.com with their article: “Why Concordia Healthcare Corp Is Shooting Higher Today” published on November 13, 2015, Benzinga.com published: “Concordia Healthcare Fell More Than Its Peers…But These Analysts Think It’s …” on October 01, 2015. More interesting news about Concordia Healthcare Corp (NASDAQ:CXRX) were released by: Seekingalpha.comand their article: “Concordia Healthcare: Opportunity” published on November 14, 2015 as well asSeekingalpha.com‘s news article titled: “Concordia Healthcare – Getting Past A Series Of Unfortunate Events” with publication date: October 29, 2015.
Concordia Healthcare Corp. is a Canada diverse healthcare company. The company has a market cap of $1.93 billion. The Firm is focused on legacy pharmaceutical products and orphan drugs. It has 24.11 P/E ratio. The Firm operates through three divisions, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc., which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran , for treatment of partial seizures in adults with epilepsy.
According to Zacks Investment Research, “Concordia Healthcare Corp. operates as a healthcare business which includes the management and acquisition of legacy pharmaceutical products and acquires and develops orphan drugs. The company’s operating segment consists of Legacy Pharmaceuticals, Specialty Healthcare Distribution and Orphan Drugs. Concordia Healthcare Corp. is headquartered in Oakville, Canada.” Get a free copy of the Zacks research report on Concordia Healthcare Corp (CXRX)
Concordia Healthcare - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.